What Is It?
The full 44-amino-acid sequence of human GHRH with one engineered modification. FDA-approved in 2010 under the brand name Egrifta. The most complete growth hormone releasing peptide ever brought to market.
Everything in one place — $4.99/mo, cancel anytime.
How Does It Work?
Sermorelin sent the first 29 words of the wake-up call. CJC-1295 took those 29 words and made them last longer. Tesamorelin delivered the full 44-word message. Binds the GHRH receptor with a stabilized N-terminus that enables survival to the pituitary. Triggers pulsatile GH release with visceral fat selectivity.
Primary Benefits (research suggests)
- 15-18% visceral fat reduction at 26 weeks (sustained at 52 weeks)
- Spares subcutaneous fat and lean muscle
- Specifically targets the deep abdominal fat tied to cardiovascular disease
Run the Numbers
Calculate your Tesamorelin reconstitution — BAC water volume, syringe units, and draw amounts. Free, no login required.
Open the Calculator →The Honest Part
- FDA-approved only for HIV-associated lipodystrophy — all other use is off-label.
- Requires chronic treatment — fat returns after stopping.
- Carries a hyperglycemia warning.
- WADA prohibited.
- For research purposes only when discussing non-approved uses.
Track Tesamorelin in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →